Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 94 entries
Sorted by: Best Match Show Resources per page
Preface.

Anticancer research

Fukushima T.
PMID: 31366564
Anticancer Res. 2019 Aug;39(8):NP.

No abstract available.

Cite
Fukushima T. Preface. Anticancer Res. 2019;39(8):NP
Fukushima, T. (2019). Preface. Anticancer research, 39(8), NP.
Fukushima, Takeo. "Preface." Anticancer research vol. 39,8 (2019): NP.
Fukushima T. Preface. Anticancer Res. 2019 Aug;39(8):NP. PMID: 31366564.
Copy Download .nbib Format: NLM
[No title available]

ESMO open

Lambertini M.
PMID: 32376765
ESMO Open. 2020 May;4:e000795. doi: 10.1136/esmoopen-2020-000795. Epub 2020 May 06.

Click here to listen to the Podcast.

Cite
Lambertini M. . ESMO Open. 2020;4:e000795doi: 10.1136/esmoopen-2020-000795.
Lambertini, M. (2020). . ESMO open, 4e000795. https://doi.org/10.1136/esmoopen-2020-000795
Lambertini, Matteo. "." ESMO open vol. 4 (2020): e000795. doi: https://doi.org/10.1136/esmoopen-2020-000795
Lambertini M. . ESMO Open. 2020 May;4:e000795. doi: 10.1136/esmoopen-2020-000795. Epub 2020 May 06. PMID: 32376765; PMCID: PMC7326248.
Copy Download .nbib Format: NLM
How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?.

Current opinion in oncology

Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A.
PMID: 31335831
Curr Opin Oncol. 2019 Sep;31(5):420-423. doi: 10.1097/CCO.0000000000000563.

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) are rapidly changing practice across different tumor settings. With this article, we reflect on how to assimilate the tsunami of ICIs data into clinical practice.RECENT FINDINGS: A tremendous increase on approvals, number...

Cite
Castelo-Branco L, Aspeslagh S, Kotecki N, et al. How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Curr Opin Oncol. 2019;31(5):420-423doi: 10.1097/CCO.0000000000000563.
Castelo-Branco, L., Aspeslagh, S., Kotecki, N., & Awada, A. (2019). How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Current opinion in oncology, 31(5), 420-423. https://doi.org/10.1097/CCO.0000000000000563
Castelo-Branco, Luís, et al. "How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?." Current opinion in oncology vol. 31,5 (2019): 420-423. doi: https://doi.org/10.1097/CCO.0000000000000563
Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A. How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Curr Opin Oncol. 2019 Sep;31(5):420-423. doi: 10.1097/CCO.0000000000000563. PMID: 31335831.
Copy Download .nbib Format: NLM
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga.

Trends in cancer

Catalano I, Grassi E, Bertotti A, Trusolino L.
PMID: 31813455
Trends Cancer. 2019 Dec;5(12):779-788. doi: 10.1016/j.trecan.2019.10.006. Epub 2019 Nov 06.

Immunotherapy with immune checkpoint inhibitors is an approved treatment option for a subpopulation of patients with colorectal cancers that display microsatellite instability. However, not all individuals within this subgroup respond to immunotherapy, and molecular biomarkers for effective patient stratification...

Cite
Catalano I, Grassi E, Bertotti A, et al. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends Cancer. 2019;5(12):779-788doi: 10.1016/j.trecan.2019.10.006.
Catalano, I., Grassi, E., Bertotti, A., & Trusolino, L. (2019). Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends in cancer, 5(12), 779-788. https://doi.org/10.1016/j.trecan.2019.10.006
Catalano, Irene, et al. "Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga." Trends in cancer vol. 5,12 (2019): 779-788. doi: https://doi.org/10.1016/j.trecan.2019.10.006
Catalano I, Grassi E, Bertotti A, Trusolino L. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends Cancer. 2019 Dec;5(12):779-788. doi: 10.1016/j.trecan.2019.10.006. Epub 2019 Nov 06. PMID: 31813455.
Copy Download .nbib Format: NLM
Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy.

Journal for immunotherapy of cancer

Zhang Y, Yao Y, Chen P, Liu Y, Zhang H, Liu H, Liu Y, Xu H, Tian X, Wang Z, Chu P, Zhao D, Liu H, Zhang C, Chen S, Zhao Y, Liu C, Yang Y.
PMID: 33109630
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001247.

BACKGROUND: Checkpoint targets play a key role in tumor-mediated immune escape and therefore are critical for cancer immunotherapy. Unfortunately, there is a lack of bioinformatics resource that compile all the checkpoint targets for translational research and drug discovery in...

Cite
Zhang Y, Yao Y, Chen P, et al. Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. J Immunother Cancer. 2020;8(2)doi: 10.1136/jitc-2020-001247.
Zhang, Y., Yao, Y., Chen, P., Liu, Y., Zhang, H., Liu, H., Liu, Y., Xu, H., Tian, X., Wang, Z., Chu, P., Zhao, D., Liu, H., Zhang, C., Chen, S., Zhao, Y., Liu, C., & Yang, Y. (2020). Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. Journal for immunotherapy of cancer, 8(2), . https://doi.org/10.1136/jitc-2020-001247
Zhang, Yixiao, et al. "Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy." Journal for immunotherapy of cancer vol. 8,2 (2020). doi: https://doi.org/10.1136/jitc-2020-001247
Zhang Y, Yao Y, Chen P, Liu Y, Zhang H, Liu H, Liu Y, Xu H, Tian X, Wang Z, Chu P, Zhao D, Liu H, Zhang C, Chen S, Zhao Y, Liu C, Yang Y. Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001247. PMID: 33109630; PMCID: PMC7592241.
Copy Download .nbib Format: NLM
Immunotherapy in prostate cancer: new horizon of hurdles and hopes.

World journal of urology

Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G.
PMID: 33106940
World J Urol. 2021 May;39(5):1387-1403. doi: 10.1007/s00345-020-03497-1. Epub 2020 Oct 26.

PURPOSE: Prostate cancer (PCa) is the most common malignancy in men and the cause for the second most common cancer-related death in the western world. Despite ongoing development of novel approaches such as second generation androgen receptor targeted therapies,...

Cite
Tsaur I, Brandt MP, Juengel E, et al. Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World J Urol. 2020;39(5):1387-1403doi: 10.1007/s00345-020-03497-1.
Tsaur, I., Brandt, M. P., Juengel, E., Manceau, C., & Ploussard, G. (2021). Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World journal of urology, 39(5), 1387-1403. https://doi.org/10.1007/s00345-020-03497-1
Tsaur, Igor, et al. "Immunotherapy in prostate cancer: new horizon of hurdles and hopes." World journal of urology vol. 39,5 (2021): 1387-1403. doi: https://doi.org/10.1007/s00345-020-03497-1
Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G. Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World J Urol. 2021 May;39(5):1387-1403. doi: 10.1007/s00345-020-03497-1. Epub 2020 Oct 26. PMID: 33106940; PMCID: PMC8514362.
Copy Download .nbib Format: NLM
Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives.

Cancer biotherapy & radiopharmaceuticals

Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G.
PMID: 32551915
Cancer Biother Radiopharm. 2021 Mar;36(2):123-132. doi: 10.1089/cbr.2020.3643. Epub 2020 Jun 16.

No abstract available.

Cite
Sardaro A, Ferrari C, Carbonara R, et al. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother Radiopharm. 2020;36(2):123-132doi: 10.1089/cbr.2020.3643.
Sardaro, A., Ferrari, C., Carbonara, R., Altini, C., Lavelli, V., & Rubini, G. (2021). Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer biotherapy & radiopharmaceuticals, 36(2), 123-132. https://doi.org/10.1089/cbr.2020.3643
Sardaro, Angela, et al. "Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives." Cancer biotherapy & radiopharmaceuticals vol. 36,2 (2021): 123-132. doi: https://doi.org/10.1089/cbr.2020.3643
Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother Radiopharm. 2021 Mar;36(2):123-132. doi: 10.1089/cbr.2020.3643. Epub 2020 Jun 16. PMID: 32551915.
Copy Download .nbib Format: NLM
Precision editing of the gut microbiota ameliorates cancer immunotherapy.

Journal of biological regulators and homeostatic agents

Franza L, Carusi V, Parrinello G, Pandolfi F.
PMID: 31833336
J Biol Regul Homeost Agents. 2019 Nov-Dec;33(6):1669-1670. doi: 10.23812/Editorial33-6-edit2.

In this editorial the authors highlight recent findings which could help design a personalized approach for cancer immunotherapy.

Cite
Franza L, Carusi V, Parrinello G, et al. Precision editing of the gut microbiota ameliorates cancer immunotherapy. J Biol Regul Homeost Agents. 2019;33(6):1669-1670doi: 10.23812/Editorial33-6-edit2.
Franza, L., Carusi, V., Parrinello, G., & Pandolfi, F. (2019). Precision editing of the gut microbiota ameliorates cancer immunotherapy. Journal of biological regulators and homeostatic agents, 33(6), 1669-1670. https://doi.org/10.23812/Editorial33-6-edit2
Franza, L, et al. "Precision editing of the gut microbiota ameliorates cancer immunotherapy." Journal of biological regulators and homeostatic agents vol. 33,6 (2019): 1669-1670. doi: https://doi.org/10.23812/Editorial33-6-edit2
Franza L, Carusi V, Parrinello G, Pandolfi F. Precision editing of the gut microbiota ameliorates cancer immunotherapy. J Biol Regul Homeost Agents. 2019 Nov-Dec;33(6):1669-1670. doi: 10.23812/Editorial33-6-edit2. PMID: 31833336.
Copy Download .nbib Format: NLM
Immunotherapy of multiple sclerosis--current status and future perspectives. September 15, 1984, Zurich, Switzerland. Abstracts.

European neurology

[No authors listed]
PMID: 4065162
Eur Neurol. 1985;24(6):433-41. doi: 10.1159/000115838.
Free Article

No abstract available.

Cite
Immunotherapy of multiple sclerosis--current status and future perspectives. September 15, 1984, Zurich, Switzerland. Abstracts. Eur Neurol. 1985;24(6):433-41doi: 10.1159/000115838.
(1985). Immunotherapy of multiple sclerosis--current status and future perspectives. September 15, 1984, Zurich, Switzerland. Abstracts. European neurology, 24(6), 433-41. https://doi.org/10.1159/000115838
"Immunotherapy of multiple sclerosis--current status and future perspectives. September 15, 1984, Zurich, Switzerland. Abstracts." European neurology vol. 24,6 (1985): 433-41. doi: https://doi.org/10.1159/000115838
Immunotherapy of multiple sclerosis--current status and future perspectives. September 15, 1984, Zurich, Switzerland. Abstracts. Eur Neurol. 1985;24(6):433-41. doi: 10.1159/000115838. PMID: 4065162.
Copy Download .nbib Format: NLM
An update on colorectal cancer microenvironment, epigenetic and immunotherapy.

International immunopharmacology

Jin K, Ren C, Liu Y, Lan H, Wang Z.
PMID: 33045561
Int Immunopharmacol. 2020 Dec;89:107041. doi: 10.1016/j.intimp.2020.107041. Epub 2020 Oct 09.

Colorectal cancer (CRC) is considered as the second most common cancer worldwide. For the past few years, the role of immunotherapy has been extensively studied and it has been demonstrated that its related approaches, such as programmed death-1 (PD-1)...

Cite
Jin K, Ren C, Liu Y, et al. An update on colorectal cancer microenvironment, epigenetic and immunotherapy. Int Immunopharmacol. 2020;89:107041doi: 10.1016/j.intimp.2020.107041.
Jin, K., Ren, C., Liu, Y., Lan, H., & Wang, Z. (2020). An update on colorectal cancer microenvironment, epigenetic and immunotherapy. International immunopharmacology, 89107041. https://doi.org/10.1016/j.intimp.2020.107041
Jin, Ketao, et al. "An update on colorectal cancer microenvironment, epigenetic and immunotherapy." International immunopharmacology vol. 89 (2020): 107041. doi: https://doi.org/10.1016/j.intimp.2020.107041
Jin K, Ren C, Liu Y, Lan H, Wang Z. An update on colorectal cancer microenvironment, epigenetic and immunotherapy. Int Immunopharmacol. 2020 Dec;89:107041. doi: 10.1016/j.intimp.2020.107041. Epub 2020 Oct 09. PMID: 33045561.
Copy Download .nbib Format: NLM
Th17 cells associated cytokines and cancer.

European review for medical and pharmacological sciences

Feng S, Chen XM, Wang JF, Xu XQ.
PMID: 27775796
Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4032-4040.

Cancer is one of the most common malignant tumors, which is a serious threat to human life. However, the etiology of cancer is not entirely clear. Under the action of tumorigenic factors, tissue cells lose normal regulation, resulting in...

Cite
Feng S, Chen XM, Wang JF, et al. Th17 cells associated cytokines and cancer. Eur Rev Med Pharmacol Sci. 2016;20(19):4032-4040
Feng, S., Chen, X. M., Wang, J. F., & Xu, X. Q. (2016). Th17 cells associated cytokines and cancer. European review for medical and pharmacological sciences, 20(19), 4032-4040.
Feng, S, et al. "Th17 cells associated cytokines and cancer." European review for medical and pharmacological sciences vol. 20,19 (2016): 4032-4040.
Feng S, Chen XM, Wang JF, Xu XQ. Th17 cells associated cytokines and cancer. Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4032-4040. PMID: 27775796.
Copy Download .nbib Format: NLM
Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic.

Cancer

Printz C.
PMID: 33460046
Cancer. 2020 Oct 15;126(20):4443-4444. doi: 10.1002/cncr.33228.

No abstract available.

Cite
Printz C. Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic. Cancer. 2020;126(20):4443-4444doi: 10.1002/cncr.33228.
Printz, C. (2020). Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic. Cancer, 126(20), 4443-4444. https://doi.org/10.1002/cncr.33228
Printz, Carrie. "Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic." Cancer vol. 126,20 (2020): 4443-4444. doi: https://doi.org/10.1002/cncr.33228
Printz C. Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic. Cancer. 2020 Oct 15;126(20):4443-4444. doi: 10.1002/cncr.33228. PMID: 33460046.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 94 entries